Randomized, Parallel-group, Double-blind, Single-center Phase III Study to Assess the Immunogenicity and Safety of the 2011/2012-season Influenza Vaccine Formulated With HA Antigen From Two Suppliers, in Elderly and Young Adult Subjects Using the Current EMA Regulations as Guideline.

Trial Profile

Randomized, Parallel-group, Double-blind, Single-center Phase III Study to Assess the Immunogenicity and Safety of the 2011/2012-season Influenza Vaccine Formulated With HA Antigen From Two Suppliers, in Elderly and Young Adult Subjects Using the Current EMA Regulations as Guideline.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2013

At a glance

  • Drugs Influenza virus vaccine liposomal (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 01 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 01 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2011 Actual initiation date Oct 2011 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top